| UniProt ID | ENC1_HUMAN | |
|---|---|---|
| UniProt AC | O14682 | |
| Protein Name | Ectoderm-neural cortex protein 1 | |
| Gene Name | ENC1 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 589 | |
| Subcellular Localization | Nucleus matrix . Cytoplasm . Cytoplasm, cytoskeleton . | |
| Protein Description | Actin-binding protein involved in the regulation of neuronal process formation and in differentiation of neural crest cells. Down-regulates transcription factor NF2L2/NRF2 by decreasing the rate of protein synthesis and not via a ubiquitin-mediated proteasomal degradation mechanism.. | |
| Protein Sequence | MSVSVHENRKSRASSGSINIYLFHKSSYADSVLTHLNLLRQQRLFTDVLLHAGNRTFPCHRAVLAACSRYFEAMFSGGLKESQDSEVNFDNSIHPEVLELLLDYAYSSRVIINEENAESLLEAGDMLEFQDIRDACAEFLEKNLHPTNCLGMLLLSDAHQCTKLYELSWRMCLSNFQTIRKNEDFLQLPQDMVVQLLSSEELETEDERLVYESAINWISYDLKKRYCYLPELLQTVRLALLPAIYLMENVAMEELITKQRKSKEIVEEAIRCKLKILQNDGVVTSLCARPRKTGHALFLLGGQTFMCDKLYLVDQKAKEIIPKADIPSPRKEFSACAIGCKVYITGGRGSENGVSKDVWVYDTLHEEWSKAAPMLVARFGHGSAELKHCLYVVGGHTAATGCLPASPSVSLKQVEHYDPTINKWTMVAPLREGVSNAAVVSAKLKLFAFGGTSVSHDKLPKVQCYDQCENRWTVPATCPQPWRYTAAAVLGNQIFIMGGDTEFSACSAYKFNSETYQWTKVGDVTAKRMSCHAVASGNKLYVVGGYFGIQRCKTLDCYDPTLDVWNSITTVPYSLIPTAFVSTWKHLPS | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 2 | Phosphorylation | ------MSVSVHENR ------CCCCCCCCC | 24.09 | 22496350 | |
| 11 | Phosphorylation | SVHENRKSRASSGSI CCCCCCCHHCCCCCE | 29.82 | 29523821 | |
| 14 | Phosphorylation | ENRKSRASSGSINIY CCCCHHCCCCCEEEE | 33.84 | 22777824 | |
| 15 | Phosphorylation | NRKSRASSGSINIYL CCCHHCCCCCEEEEE | 35.26 | 22777824 | |
| 17 | Phosphorylation | KSRASSGSINIYLFH CHHCCCCCEEEEEEE | 17.89 | 29523821 | |
| 26 | Phosphorylation | NIYLFHKSSYADSVL EEEEEECHHHHHHHH | 21.73 | 28258704 | |
| 27 | Phosphorylation | IYLFHKSSYADSVLT EEEEECHHHHHHHHH | 29.19 | 28258704 | |
| 28 | Phosphorylation | YLFHKSSYADSVLTH EEEECHHHHHHHHHH | 22.86 | 28258704 | |
| 31 | Phosphorylation | HKSSYADSVLTHLNL ECHHHHHHHHHHHHH | 15.74 | 28258704 | |
| 34 | Phosphorylation | SYADSVLTHLNLLRQ HHHHHHHHHHHHHHH | 23.35 | 28258704 | |
| 46 | Phosphorylation | LRQQRLFTDVLLHAG HHHHHHHHHHHHCCC | 29.77 | 24719451 | |
| 70 | Phosphorylation | VLAACSRYFEAMFSG HHHHHHHHHHHHHCC | 6.89 | - | |
| 168 | Phosphorylation | CTKLYELSWRMCLSN HHHHHHHHHHHHHHC | 10.74 | 24719451 | |
| 213 | Phosphorylation | DERLVYESAINWISY HHHHHHHHHHHHHCC | 19.43 | 26270265 | |
| 219 | Phosphorylation | ESAINWISYDLKKRY HHHHHHHCCCHHHCC | 12.28 | 26270265 | |
| 220 | Phosphorylation | SAINWISYDLKKRYC HHHHHHCCCHHHCCC | 19.03 | 26270265 | |
| 245 | Phosphorylation | LALLPAIYLMENVAM HHHHHHHHHHHHHHH | 11.34 | 22817900 | |
| 263 | Ubiquitination | ITKQRKSKEIVEEAI HHHHHHCHHHHHHHH | 55.27 | - | |
| 285 | Phosphorylation | QNDGVVTSLCARPRK CCCCCEEEEECCCCC | 15.16 | 24719451 | |
| 304 | Phosphorylation | LFLLGGQTFMCDKLY EEEECCCEECCCEEE | 19.33 | 19690332 | |
| 316 | Ubiquitination | KLYLVDQKAKEIIPK EEEECCHHHHHHCCC | 57.89 | - | |
| 318 | Ubiquitination | YLVDQKAKEIIPKAD EECCHHHHHHCCCCC | 57.38 | - | |
| 331 | Ubiquitination | ADIPSPRKEFSACAI CCCCCCCHHHCCCEE | 67.50 | - | |
| 406 | Phosphorylation | ATGCLPASPSVSLKQ CCCCCCCCCCCCHHH | 18.77 | 30576142 | |
| 408 | Phosphorylation | GCLPASPSVSLKQVE CCCCCCCCCCHHHCE | 23.11 | 22617229 | |
| 410 | Phosphorylation | LPASPSVSLKQVEHY CCCCCCCCHHHCEEC | 33.90 | 26434776 | |
| 417 | Phosphorylation | SLKQVEHYDPTINKW CHHHCEECCCCCCEE | 15.31 | - | |
| 423 | Ubiquitination | HYDPTINKWTMVAPL ECCCCCCEEEEEEEC | 39.94 | - | |
| 435 | Phosphorylation | APLREGVSNAAVVSA EECCCCCCHHHHHHH | 31.44 | 17924679 | |
| 441 | Phosphorylation | VSNAAVVSAKLKLFA CCHHHHHHHEEEEEE | 17.06 | 17924679 | |
| 443 | Ubiquitination | NAAVVSAKLKLFAFG HHHHHHHEEEEEEEC | 38.35 | 21906983 | |
| 452 | Phosphorylation | KLFAFGGTSVSHDKL EEEEECCCCCCCCCC | 26.74 | - | |
| 453 | Phosphorylation | LFAFGGTSVSHDKLP EEEECCCCCCCCCCC | 25.54 | - | |
| 455 | Phosphorylation | AFGGTSVSHDKLPKV EECCCCCCCCCCCCC | 26.24 | - | |
| 520 | Ubiquitination | SETYQWTKVGDVTAK CCEEEEEEECCEEEC | 41.06 | 21906983 | |
| 527 | Ubiquitination | KVGDVTAKRMSCHAV EECCEEECCCEEEEE | 38.99 | 21906983 | |
| 530 | Phosphorylation | DVTAKRMSCHAVASG CEEECCCEEEEEEEC | 13.54 | 24425749 | |
| 541 | Phosphorylation | VASGNKLYVVGGYFG EEECCEEEEECCEEC | 8.49 | 24425749 | |
| 569 | Phosphorylation | LDVWNSITTVPYSLI CCCHHCCCCCCHHHC | 22.89 | 18452278 | |
| 570 | Phosphorylation | DVWNSITTVPYSLIP CCHHCCCCCCHHHCC | 20.15 | 18452278 | |
| 573 | Phosphorylation | NSITTVPYSLIPTAF HCCCCCCHHHCCCHH | 16.27 | 18452278 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of ENC1_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of ENC1_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of ENC1_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| CUL3_HUMAN | CUL3 | physical | 15983046 | |
| RBX1_HUMAN | RBX1 | physical | 15983046 | |
| ACTB_HUMAN | ACTB | physical | 15208678 | |
| NF2L2_HUMAN | NFE2L2 | physical | 20511222 | |
| ENC1_HUMAN | ENC1 | physical | 16306221 | |
| ENC1_HUMAN | ENC1 | physical | 15983046 | |
| SQSTM_HUMAN | SQSTM1 | physical | 26637326 | |
| KLH25_HUMAN | KLHL25 | physical | 28514442 | |
| NUDC3_HUMAN | NUDCD3 | physical | 28514442 | |
| PLIN5_HUMAN | PLIN5 | physical | 28514442 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Improved titanium dioxide enrichment of phosphopeptides from HeLacells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra."; Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; J. Proteome Res. 6:4150-4162(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-435 AND SER-441, ANDMASS SPECTROMETRY. | |